Table 2.
In-hospital management and outcomes of ACEi/ARB and non-ACEI/ARB groups.
| Variable | Non-ACEi/ARB | ACEi/ARB | p-value |
|---|---|---|---|
| (n = 173) | (n = 103) | ||
| Interferon-α | 110 (63.58%) | 64 (63.37%) | 0.971 |
| Oseltamivir | 3 (1.73%) | 5 (4.95%) | 0.149 |
| Fapiravir | 6 (3.47%) | 5 (5.00%) | 0.535 |
| Arbidol | 127 (73.41%) | 71 (70.30%) | 0.579 |
| Lopinavir/ritonavir | 96 (55.49%) | 61 (60.40%) | 0.428 |
| Darunavir | 3 (1.84%) | 2 (2.27%) | 1 |
| Chloroquine phosphate | 2 (1.23%) | 1 (1.14%) | 0.95 |
| Glucocorticoids | 60 (34.68%) | 33 (32.04%) | 0.653 |
| IVIGt | 47 (27.17%) | 25 (24.27%) | 0.596 |
| Antibiotics drug | 80 (46.24%) | 45 (43.69%) | 0.68 |
| Antihypertensive agents | |||
| Calcium channel blockers | 137 (82.66%) | 47 (45.63%) | <0.001 |
| ACEi | 0 (0.00%) | 12 (11.65%) | <0.001 |
| ARB | 0 (0.00%) | 91 (88.35%) | <0.001 |
| Beta-blockers | 20 (11.56%) | 7 (6.80%) | 0.198 |
| Diuretics | 34 (19.65%) | 12 (11.65%) | 0.084 |
| Centrally antihypertensive agents | 3 (1.73%) | 0 (0.00%) | 0.296 |
| Shock | 1 (0.55%) | 1 (0.97%) | 1 |
| Admission to ICU | 24 (13.87%) | 10 (9.71%) | 0.309 |
| Mechanical Ventilation | 22 (12.72%) | 9 (8.74%) | 0.311 |
| Venovenous hemofiltration | 3 (1.73%) | 1 (0.97%) | 1 |
| ECMO | 6 (3.47%) | 2 (1.94%) | 0.714 |
| Lung transplantation | 1 (0.97%) | 0 (0.00%) | 1 |
| Composite endpoint | 31 (17.92%) | 13 (12.62%) | 0.245 |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation; IVIGt, intravenous immunoglobulin treatment.